|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 抗溃疡性结肠炎治疗药物的研究进展显示文摘溃疡性结肠炎(UC)是一种慢性、非特异性炎症性肠病,病变主要涉及乙状结肠、直肠黏膜及其下层。其发病机制复杂,与免疫因素及炎性介质等因素共同作用有关。其特点是病程长,经常复发,迁延难愈,难以根治,且易发生癌变,是目前公认的较难治愈的病症之一。UC目前主要的治疗方式是抗炎以及调节免疫反应,随着研究的深入,许多新型的药物制剂和全新的治疗方法开始逐渐应用于临床。与其他治疗药物相比,氨基水杨酸类药物是当前临床使用疗效较好的药物,为UC的治疗带来了广阔的发展前景,同时也给患者及研究人员提供了用药参考。 | 迟伟男 刘哲鹏 | 2019 | 医学综述2019，25，4： | 34 |
| 2 | 巴柳氮、美沙拉嗪和柳氮磺吡啶治疗活动性溃疡性结肠炎的荟萃分析显示文摘目的:评价巴柳氮、美沙拉嗪和柳氮磺吡啶治疗活动性溃疡性结肠炎(UC)的疗效与安全性,并探讨三种药物不同的药物动力学.方法:检索Medline、EMBASE、OVID、Cochrane Library、Cinahl、CESJ、ASP、VIP和CNKI中国期刊全文数据库2008-07-01前已发表的关于巴柳氮、美沙拉嗪和柳氮磺吡啶相互比较治疗活动性UC的随机对照临床试验研究.再通过手工检索2008-01/2008-06已发表的关于三种药物相互比较治疗活动性溃疡性结肠炎的随机对照临床试验研究.利用Stata9.0软件进行荟萃分析.结果:按入选标准,共纳入10个随机对照临床试验,共1119例UC患者纳入荟萃分析.巴柳氮与柳氮磺吡啶相比,其疗效相似(OR=1.24,95%CI:0.80-1.93,P=0.345),副作用发生率低(OR=0.27,95%CI:0.13-0.59,P=0.001),副作用致停药率低(OR=0.12,95%CI:0.03-0.44,P=0.002).巴柳氮与美沙拉嗪相比,疗效相似(OR=1.55,95%CI:1.00-2.42,P=0.051),副作用发生率低(OR=0.59,95%CI:0.39-0.90,P=0.014),副作用致停药率相似(OR=1.34,95%CI:0.29-6.22,P=0.709).美沙拉嗪与柳氮磺吡啶相比,疗效相似(OR=0.71,95%CI:0.19-2.59,P=0.599),副作用发生率低(OR=0.44,95%CI:0.27-0.71,P=0.001),副作用致停药率相似(OR=0.69,95%CI:0.26-1.88,P=0.470).结论:巴柳氮、美沙拉嗪和柳氮磺吡啶均能有效的治疗活动性UC,而巴柳氮和美沙拉嗪副作用发生率低于柳氮磺吡啶副作用发生率;偶氮5-ASA前药可能较5-ASA控释剂更能有效地治疗UC. | 张智峰 段志军 赵钢 刘丽娜 王英德 | 2008 | 世界华人消化杂志2008，16，30： | 25 |
| 3 | 氨基水杨酸类联合微生态制剂对溃疡性结肠炎的维持治疗进展显示文摘溃疡性结肠炎(UC)在治疗上缺乏特异性措施,常用药物如氨基水杨酸类、糖皮质激素、免疫抑制剂的大剂量、长期使用,可导致严重并发症,且在维持治疗阶段易复发。近年研究发现,氨基水杨酸类联合微生态制剂对UC的维持治疗效果较好,本文就氨基水杨酸类联合微生态制剂对UC维持治疗的研究进展进行综述。 | 王赛 周国华 | 2015 | 实用药物与临床2015，18，4： | 26 |
| 4 | Colorectal cancer in inflammatory bowel disease:What is the real magnitude of the risk?显示文摘The association between inflammatory bowel disease(IBD) and colorectal cancer(CRC) has been recognised since 1925 and still accounts for 10%-15% of deaths in IBD.IBD-associated CRC(IBD-CRC) affects patients at a younger age than sporadic CRC.The prognosis for sporadic CRC and IBD-CRC is similar,with a 5-year survival of approximately 50%.Identifying at risk patients and implementing appropriate surveillance for these patients is central to managing the CRC risk in IBD.The increased risk of colorectal cancer in association with IBD is thought to be due to genetic and acquired factors.The link between inflammation and cancer is well recognised but the molecular biology,immune pathobiology and genetics of IBD-CRC are areas of much ongoing research.This review examines the literature relating to IBD-CRC,focusing on the incidence of IBD-CRC and examining potential risk factors including age at diagnosis,gender,duration and extent of colitis,severity of inflammation,family history of sporadic CRC and co-existent primary sclerosing cholangitis(PSC).Confirmed risk factors for IBD-CRC are duration,severity and extent of colitis,the presence of co-existent PSC and a family history of CRC.There is insufficient evidence currently to support an increased frequency of surveillance for patients diagnosed with IBD at a younger age.Evidence-based guidelines advise surveillance colonoscopy for patients with colitis 8 to 10 years after diagnosis,with the interval for further surveillance guided by risk factors(extent of disease,family history of CRC,post-inflammatory polyps,concomitant PSC,personal history of colonic dysplasia,colonic strictures).There is a move away from using random colonic biopsies towards targeted biopsies aimed at abnormal areas identified by newer colonoscopic techniques(narrow band imaging,chromoendoscopy,confocal microendoscopy). | Jessica K Dyson Matthew D Rutter | 2012 | World Journal of Gastroenterology2012，18，29： | 22 |
| 5 | Timing of surgery in Crohn’s disease: A key issue in the management显示文摘The timing of the decision for operation in Crohn’s disease is based on an evaluation of the several factors such as the failure of medical treatment, complications due to the Crohn’s disease or to the farmacological therapy, development of dysplasia or cancer and growth retardation. A complete evaluation of these factors should result in operation timed to the patient’s best advantage, achieving maximal relief of symptoms with improvement of quality of life. Given the complexity and heterogeneity of the disease and the different options for treatment, is difficult to systematize when the optimal moment for the surgery is arrived. A very important factor in the management of Crohn’s disease is the multidisciplinary approach and the patient preference should be a significant factor in determining the choice of therapy. The surgery should be considered such another option in the sequential treatment of Crohn’s disease. We have analyzed the factors that are involved in the decision taking of the surgical treatment regarding to the experience and the published literature. When did the medical therapy fail? when is the appropriate moment to operate on the patient? Or which complications of Crohn’s disease need a surgery? These are some of the questions we will try to answer. | Rafael Alós Joaquín Hinojosa | 2008 | World Journal of Gastroenterology2008，14，36： | 11 |
| 6 | Update on inflammatory bowel disease in patients with primary sclerosing cholangitis显示文摘Patients with primary sclerosing cholangitis(PSC) complicated by inflammatory bowel disease(IBD) represent a distinct subset of patients with unique characteristics,which have serious clinical implications.The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective.The prevalence of IBD,mainly ulcerative colitis in PSC patients is estimated to be 21%-80%,dependent on screening programs and nationality.PSC-associated colitis is likely to be extensive,characterized by rectal sparing,backwash ileitis,and generally mild symptoms.It is also more likely to progress to colorectal malignancy,making it imperative for clinicians to maintain a high level of suspicion when tackling PSC patients.There is no optimal surveillance strategy but current guidelines advocate that colonoscopy is necessary at the time of PSC diagnosis with annual endoscopic follow-up.Random biopsies have been criticized and a shift towards targeted biopsies using chromoendoscopy,laser endomicroscopy and narrow-band imaging has been noted.Techniques directed towards genetic mutations instead of histological abnormalities hold promise for easier,more accurate diagnosis of dysplastic lesions.Chemopreventive measures against colorectal cancer have been sought in these patients.Ursodeoxycholic acid seemed promising at first but subsequent studies yielded conflicting results showing anticarcinogenic effects in low doses(8-15 mg/kg per day) and carcinogenic properties in high doses(15-30 mg/kg per day). | Christos Tsaitas Anysia Semertzidou Emmanouil Sinakos | 2014 | World Journal of Hepatology2014，6，4： | 9 |
| 7 | 化浊解毒方治疗溃疡性结肠炎的疗效分析显示文摘目的观察化浊解毒方治疗溃疡性结肠炎(UC)的临床疗效。方法收治的120例患者按随机数字表法分为观察组和对照组,每组60例。入组病例共脱落7例,观察组3例(失访),对照组4例(失访)。符合研究方案的病例共113例,其中观察组57例,对照组56例。观察组给予化浊解毒方(水煎服,1剂/d),对照组给予美沙拉嗪肠溶片(每次1 g,3次/d),疗程均为4周,观察治疗前后患者临床症状、生活质量及结肠镜变化。结果与治疗前比较,2组患者接受治疗后各症状积分均下降(P<0.05);治疗后与对照组比较,观察组腹泻、腹痛、里急后重、腹胀积分降低明显(P<0.05)。治疗后治疗组0级、Ⅰ级肠镜例数均多于对照组,差异有统计学意义(P<0.05)。与治疗前比较,治疗后2组患者情感功能、全身症状、肠道症状、社会功能评分及总评分均升高(P<0.05);与对照组比较,观察组治疗后全身症状、情感功能、肠道症状评分及总评分升高(P<0.05)。结论化浊解毒方能够有效缓解UC患者临床症状,改善镜下病理变化,提高患者的生活质量。 | 李博林 白亚楠 景璇 何芳 梁亚飞 才艳茹 杜朋丽 赵丹阳 杨倩 | 2019 | 河北医药2019，41，17： | 9 |
| 8 | 炎症性肠病并发结直肠癌的相关研究动态显示文摘炎症性肠病(inflammatory bowel disease,IBD)是慢性非特异性肠道疾病。近年来大量流行病学调查研究发现炎症性肠病和结直肠癌之间存在着一定关系。本次研究主要对IBD并发结直肠癌的现状, | 唐凯 王建国 | 2010 | 全科医学临床与教育2010，8，6： | 6 |
| 9 | State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008显示文摘Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are two of the leading causes of chronic intestinal conditions in the world. This issue of World Journal of Gastroenterology (WJG ) presents a series of papers from world experts who discuss the current knowledge and opinions on these important conditions. Although great strides have been made in the diagnosis, treatment and pathology of IBS and IBD; much has yet to be explained. The etiologies and risk factors of these multifactorial conditions remain elusive. Specific diagnostic biomarkers need to be developed and safer treatments developed. The burden of IBS and IBD on the healthcare system is felt with repeated medical care visits and high costs. IBS and IBD patients can account for 30%-50% of office visits at gastroenterology services/clinics. Over one million people have IBD in the United States, with 30 000 new cases being diagnosed every year. One-quarter million people in the UK are afflicted with IBD. The cost of medical care in the United States for IBD is estimated to be $1.8 billion/year. | Lynne V McFarland | 2008 | World Journal of Gastroenterology2008，14，17： | 6 |
| 10 | Potential of soluble CD26 as a serum marker for colorectal cancer detection显示文摘Colorectal cancer is characterized by a low survival rate even though the basis for colon cancer development,which involves the evolution of adenomas to carcinoma,is known.Moreover,the mortality rates continue to rise in economically transitioning countries although there is the opportunity to intervene in the natural history of the adenoma–cancer sequence through risk factors,screening,and treatment.Screening in particular accounted for most of the decline in colorectal cancer mortality achieved in the USA during the period 1975-2000.Patients show a better prognosis when the neoplasm is diagnosed early.Among the variety of screening strategies,the methods range from invasive and costly procedures such as colonoscopy to more low-cost and non-invasive tests such as the fecal occult blood test(guaiac and immunochemical).As a non-invasive biological serum marker would be of great benefit because of the performance of the test,several biomarkers,including cytologic assays,DNA and mRNA,and soluble proteins,have been studied.We found that the soluble CD26(sCD26)concentration is diminished in serum of colorectal cancer patients compared to healthy donors,suggesting the potential utility of a sCD26 immunochemical detection test for early diagnosis.sCD26 originates from plasma membrane CD26 lacking its transmembrane and cytoplasmic domains.Some 90%–95%of sCD26 has been associated with serum dipeptidyl peptidase IV(DPPIV)activity.DPP-IV,assigned to the CD26 cluster,is a pleiotropic enzyme expressed mainly on epithelial cells and lymphocytes.Our studies intended to validate this test for population screening to detect colorectal cancer and advanced adenomas are reviewed here. | Oscar J Cordero Monica Imbernon Loretta De Chiara Vicenta S Martinez-Zorzano Daniel Ayude Maria Paez de la Cadena F Javier Rodriguez-Berrocal | 2011 | World Journal of Clinical Oncology2011，2，6： | 5 |
| 11 | 溃疡性结肠炎缓解期维持治疗的价值显示文摘目的探讨缓解期维持治疗对于溃疡性结肠炎(ulcerative colitis,UC)治疗的价值。方法依据是否维持治疗分为维持治疗组和非维持治疗组,比较两组患者的复发情况、病情进展、黏膜愈合、癌变率、平均住院日、平均治疗费用等指标。结果维持治疗组与非维持治疗组比较,在疾病复发率、病情进展率、黏膜愈合率、癌变率、平均住院日、年人均费用比较,差异均有统计学意义(P<0.05)。结论缓解期的维持治疗,对于UC的治疗有着极其重要的价值。 | 侯叶廷 苏秉忠 陈平 黄应龙 | 2015 | 胃肠病学和肝病学杂志2015，24，7： | 3 |
| 12 | 炎症性肠病与肿瘤显示文摘癌变是炎症性肠病(IBD)最严重的并发症之一。IBD相关的肿瘤与散发性肿瘤的临床特点并不完全相同。重视相关危险因素,凭借内镜新技术,IBD相关肿瘤的早期诊断将有助于提高患者的生活质量和生存机会。为提高对IBD相关肿瘤的认识及重视,本文就IBD相关肿瘤的发病情况、临床特点及危险因素等作一综述。 | 赵玉洁 袁耀宗 | 2009 | 世界临床药物2009，30，8： | 1 |
| 13 | 溃疡性结肠炎相关结直肠癌和非典型增生的研究进展显示文摘长期溃疡性结肠炎病史者结直肠癌的发病率明显增加。目前已知的危险因素包括多年病史、广泛结肠受累、结肠炎症程度、结直肠癌家族史、合并原发性硬化性胆管炎等。发病的分子机制主要是染色体不稳定性和微卫星不稳定性。对多年病史者尤其是高危患者应行结肠镜筛查,同时应给予化学预防以减少肿瘤的发生。新的内镜技术提高了肿瘤检测的敏感性,为肿瘤筛查提供了更可靠的方法。 | 周艳华 张澍田 | 2011 | 国际外科学杂志2011，38，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员